Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17607654 | 0.93 | MEN1 (0.38) | MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL10412583 | 0.84 | ACE2 (0.38) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL1971579 | 0.83 | — | — | |
| SCHEMBL5963220 | 0.83 | ACE2 (0.37) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL8949649 | 0.81 | LMNA (0.36) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL306062 | 0.80 | LMNA (0.48) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL9490940 | 0.80 | MEN1 (0.32) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL28722883 | 0.80 | LMNA (0.37) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL1872786 | 0.79 | LMNA (0.35) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL4900666 | 0.79 | LMNA (0.35) | MEN1CYP3A4ALOX15KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716506-A | Hemiasterlin derivatives for conjugation and therapy | 苏特罗生物制药公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-3194371-B1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | AGENCY SCIENCE TECH & RES (SG) | 2020-09-02 | — | — | EP | disclosed |
| US-10570097-B2 | Antimicrobial imidazolium compounds | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-02-25 | — | — | US | disclosed |
| US-10344389-B2 | Low temperature electrolytes for solid oxide cells having high ionic conductivity | FCET, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190016684-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-01-17 | — | — | US | disclosed |
| US-10160728-B2 | Antimicrobial imidazolium compounds | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-12-25 | — | — | US | disclosed |
| US-20180023205-A1 | Low Temperature Electrolytes for Solid Oxide Cells Having High Ionic Conductivity | FCET, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20170291877-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-10-12 | — | — | US | disclosed |
| CN-107108518-A | Antibacterial imidazolium compounds | 新加坡科技研究局 | 2017-08-29 | — | — | CN | disclosed |
| EP-3194371-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | Agency for Science, Technology and Research (SG) | 2017-07-26 | — | — | EP | disclosed |
| US-6911424-B2 | 2′-fluoronucleosides | EMORY UNIVERSITY (US) | 2005-06-28 | — | — | US | disclosed |
| US-20050119286-A1 | BETA-2'-OR 3'-HALONUCLEOSIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-02 | — | — | US | disclosed |
| US-20040254141-A1 | 2'-Fluoronucleosides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-12-16 | — | — | US | disclosed |
| EP-1478322-A2 | Beta-2'-OR 3'-HALONUCLEOSIDES | Pharmasset Limited (BB) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003000200-A2 | β-2'-OR 3'-HALONUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-01-03 | — | — | WO | disclosed |
| US-20020198171-A1 | 2'-fluoronucleosides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-26 | — | — | US | disclosed |
| EP-1112272-B1 | MUSCARINIC AGONISTS AND ANTAGONISTS | UCB SA (BE) | 2002-11-13 | — | — | EP | disclosed |
| US-6348587-B1 | PURINE OR PYRIMIDINE BASE DERIVATIVES; ANTICANCER, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS; TREATING HIV AND HEPATITIS | EMORY UNIVERSITY | 2002-02-19 | — | — | US | disclosed |
| EP-1058686-A1 | 2'-FLUORONUCLEOSIDES | EMORY UNIVERSITY (US) | 2000-12-13 | — | — | EP | disclosed |
| WO-1999043691-A1 | 2'-FLUORONUCLEOSIDES | EMORY UNIVERSITY (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198171-A1 | 2'-fluoronucleosides | NSUN2, PNP, FDPS | MEN1 2110/4885CYP3A4 1881/4885ALOX15 3774/4885 |
| US-10570097-B2 | Antimicrobial imidazolium compounds | CCNI, MACF1, ECI1 | MEN1 3567/4885CYP3A4 1947/4885ALOX15 1132/4885 |
| US-20040254141-A1 | 2'-Fluoronucleosides | NSUN2, PNP, FDPS | MEN1 2110/4885CYP3A4 1881/4885ALOX15 3774/4885 |
| US-20050119286-A1 | BETA-2'-OR 3'-HALONUCLEOSIDES | MKI67, EBP, PCNA | MEN1 3605/4885CYP3A4 3012/4885ALOX15 3704/4885 |
| US-10160728-B2 | Antimicrobial imidazolium compounds | CCNI, MACF1, ECI1 | MEN1 3567/4885CYP3A4 1947/4885ALOX15 1132/4885 |
| US-20170291877-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | CCNI, MACF1, ECI1 | MEN1 3567/4885CYP3A4 1947/4885ALOX15 1132/4885 |
| US-20190016684-A1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | CCNI, MACF1, ECI1 | MEN1 3567/4885CYP3A4 1947/4885ALOX15 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.